Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
ALR Technologies SG Ltd has signed a letter of intent to acquire CGM Medical Technology’s Singapore and Shenzhen operations for $45 million and 200 million shares, aiming to integrate continuous glucose monitor production.
Inductive Bio has joined Anthropic's life sciences ecosystem and launched a connector that integrates its ADMET prediction models into Claude, allowing scientists to analyze drug properties directly within the AI assistant.
Basecamp Research has made its EDEN antibiotic and vaccine design models available through Anthropic's Claude Science, allowing researchers to generate and prioritize therapeutic candidates using a conversational interface.
SciBase has submitted a 510(k) premarket notification to the U.S. FDA to expand the use of its AI device Nevisense to include non-melanoma skin cancers, aiming to broaden its clinical application beyond melanoma.
PreOncology has introduced a new oncologist-led medical specialty focused on preventing and detecting cancer before stage I, combining genomics, AI risk modeling, and personalized surveillance through its Stage Alpha Operating System.
LatusPet, a University of Oxford biotech startup, has published a peer-reviewed study demonstrating that its SINO platform can detect multiple diseases in dogs from a single blood sample with over 90% accuracy.
Caris Life Sciences has launched Caris Detect, a blood test that uses whole genome and transcriptome sequencing with artificial intelligence to identify early cancer signals across multiple cancer types.
One Brooklyn Health has chosen hellocare.ai to implement AI assisted virtual nursing and patient monitoring across its hospitals, introducing real time AI models for fall prevention and patient safety.
Ozelle will debut its new automated hematology analyzer, O-Cyte 1, at ADLM 2026 in California. The system uses AI to deliver morphology intelligence and scalable throughput for clinical laboratories.
Xellar Biosystems has secured $50 million in Series A and A+ funding to advance its 3D Bio Intelligence platform that integrates organ-on-chip systems, automation, imaging, multi-omics, and AI modeling for drug discovery.
4DMedical has received approval from the Australian Therapeutic Goods Administration for its CT:VQ imaging technology, enabling contrast-free ventilation and perfusion imaging using standard chest CT scans.
RADIN Health has deployed its cloud-based radiology platform at four additional hospitals within the UHS Nevada Health System, bringing its total presence in the state to eight facilities.
UpDoc has received FDA clearance for its Software as a Medical Device, the first to use patient-facing large language models for clinical care delivery. The platform has also begun deployment at four major health systems and secured $18 million in seed funding.
Aidoc has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its AI tool First Read, which generates preliminary radiology report text from chest radiographs to help reduce reporting time and support radiologists facing growing imaging demand.
Biolevate is integrating NVIDIA BioNeMo Agent Toolkit and GPU-optimized pipelines into its OCEAN technology stack to enhance AI-based drug discovery workflows and improve RNA model predictions.
Upside has raised $20 million in a Series A round led by Aquiline Capital Partners and Flare Capital Partners to expand its AI supported housing stability platform for healthcare across the United States.
A study published in JAMA Network Open found that Clairyon's AI Clinical Abstraction Agent improved SEP-1 sepsis care compliance by 13 percent across two emergency departments.
Veeva Systems has launched Veeva EHS, a new application within its Veeva Quality Cloud platform, aimed at improving environmental, health, and safety management through real-time insights and intelligent automation. The application will be available to early adopters in August 2026.
A prospective study found that Castle Biosciences' DecisionDx-Melanoma i31-SLNB test more accurately identifies melanoma patients who may safely avoid sentinel lymph node biopsy compared to the Melanoma Institute Australia nomogram.
Attune has received a strategic growth investment from Chicago Pacific Founders to expand its healthcare engagement platform, which connects fragmented care systems and improves coordination across health plans and providers.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
